Vivus (VVUS) C.E. Unterberg, Towbin raised its rating to "strong buy," pointing to important progress trials of the Vivus product Allista for the treatment of female sexual dysfunction.
VIVUS goal is to establish a robust pipeline consisting of drug candidates at various stages of development, with a focus on innovative therapies intended to serve large and unsatisfied markets. In addition to the Companys currently marketed products, MUSE. and ACTIS., VIVUS is developing products for male erectile dysfunction, female sexual dysfunction, and premature ejaculation. The Company believes that patients with these conditions are not being adequately treated, and VIVUS has the expertise and intellectual property necessary to make meaningful contributions in these areas.
GO to WWW.VIVUS.COM for complete product pipeline information.
CONTACT: VIVUS Inc.
Richard Walliser, 650/934-5200
ir@vivus.com
www.vivus.com
or
Lippert/Heilshorn & Associates Inc.
Bruce Voss, 310/691-7100 (Investor Contacts)
bvoss@lhai.com
Jody Cain, 310/691-7100 (Investor Contacts)
jcain@lhai.com
Elissa Grabowski, 212/838-3777 (Media Contact)
egrabowski@lhai.com
www.lhai.com |
